中国"AI六小龙"在上市与融资的路径上出现了明显分化。智谱与MiniMax先后在港股敲钟，但上市后股价承压。其中智谱2025年营收7.24亿元，净亏损达47.18亿元，亏损规模是营收的6.5倍[1]；MiniMax同期总收入7903.8万美元，年内总亏损高达18.72亿美元[1]。相比之下，月之暗面与阶跃星辰正在冲刺IPO阶段，月之暗面半年内估值从43亿美元跃升至500亿美元的目标[1]，阶跃星辰Pre-IPO融资投前估值从40亿美元升至50亿-60亿美元，市场预期上市基石定价有望触及100亿美元[1]。
与此同时，百川智能与零一万物则采取了不同的战略路径。百川智能在2024年7月完成50亿元A轮融资后，宣布放弃通用大模型赛道转向医疗领域[1]；零一万物在2025年实现经审计收入2.5亿元，锁定合同订单5亿元，年运营成本2亿多元[1]。这些公司的分化反映出大模型行业的评判标准已从技术叙事转向商业现实，从模型参数转向收入质量、成本结构与生态位[1]。
China's leading independent large language model startups—collectively known as the "AI Six Dragons"—have charted sharply different trajectories over the past three years, with their fortunes increasingly determined by commercial viability rather than technological prowess. [1]
Zhipu AI and MiniMax achieved public market listings in January 2026, but both face investor skepticism about their financial performance. [1] Zhipu reported 2025 revenues of 724 million yuan while posting a net loss of 4.718 billion yuan, meaning losses exceeded revenue by 6.5 times. [1] MiniMax generated total revenue of 79.038 million U.S. dollars in the same period yet accumulated annual losses of 1.872 billion dollars. [1] In contrast, Moonshot AI and StepFun are pursuing aggressive growth strategies toward initial public offerings. Moonshot's valuation surged from 4.3 billion dollars to a targeted 50 billion dollars within six months. [1] StepFun's pre-IPO financing round valued the company at between 5 billion and 6 billion dollars, with market expectations that its listing anchor price could reach 10 billion dollars. [1] However, StepFun's 2025 revenues fell short of 500 million yuan while the company remained in "substantial loss-making status." [1]
Meanwhile, the remaining two players have abandoned the crowded general-purpose AI model sector. Zero One Everything achieved audited 2025 revenues of 250 million yuan with locked-in contract orders of 500 million yuan and annual operating costs exceeding 200 million yuan. [1] Baichuan Intelligence completed a Series A funding round of 5 billion yuan in July 2024 at a 20 billion yuan valuation, then announced its pivot from general large models to the healthcare sector. [1]